Clinical Pharmacists Participating in Diagnosis and Treatment of One Case of Pulmonary Mucormycosis Infection and Literature Analysis

OBJECTIVE To explore the role of clinical pharmacists played in the clinical practice of patients with diabetic ketoacidosis and pulmonary mucormycosis infection. METHODS Clinical pharmacists participated in the treatment progress for one case of diabetic ketoacidosis complicated with pulmonary mucormycosis infection, provided pharmaceutical care in terms of medical history, risk factors analysis, drug selection, mode of administration, dosage, adverse reaction monitoring and medication education. RESULTS Amphotericin B 25 mg intravenous drip qd and 5 mg aerosol inhalation bid were given individually according to patient's age, economic condition, renal function and tolerance. The levels of renal function and electrolyte K⁺ were monitored and processed accordingly. The patient's condition improved with no serious adverse reactions, and the vital signs were stable and discharged. CONCLUSION Clinical pharmacists can assist physicians to formulate safe and effective treatment for pulmonary mucormycosis patients, carry out pharmaceutical care, prevent adverse reactions, and promote clinical rational drug use.